Overview
Chemanex supplies specialised industrial chemicals and technical solutions across manufacturing markets, supported by distribution, formulation advice and strategic investments. The latest quarter showed a substantial improvement in operating performance, with stronger profitability despite only moderate revenue expansion.
Price performance
At LKR 159 on 2026-08-07, Chemanex's one-year return was -7.7%, against a 9.5% gain for the ASPI. Over three months, the share fell 3.4% while the index fell 7.1%, indicating relative resilience over that shorter window despite the longer-term lag.
The share sat at 24.1% of its 52-week range, close to its low rather than its high. Recent volatility was 1.8% below its own one-year norm, while 20-day average volume was 74.2% below its 60-day average, pointing to a quieter market in the stock rather than a broad trading surge.
Valuation
Chemanex trades on a P/E of 12.55, broadly around the manufacturing sector's middle, but its P/B is at the sector's 0th percentile. The low book multiple is notable alongside annual ROE of 3.9%, which indicates that the discount is not being supported by strong returns on owners' equity.
The dividend yield is 1.6%, and the payout has not followed a steady growth path: dividend per share fell from LKR 7.36 in FY2025 to LKR 2.5 in FY2026. The yield therefore offers limited support unless earnings and distributions become more consistent.
News and sentiment
Coverage is thin: only one material company article appeared in the 90-day window, and it was neutral. The article reported the FY2026 final dividend, which went ex-dividend on 2026-07-01 and was payable on 2026-07-20; no undated corporate action is pending in the supplied data.
Financials
The June 2026 quarter delivered gross margin of 29.9%, operating margin of 32.4% and net margin of 28.1%, compared with 24.2%, 19.3% and 15.2% respectively a year earlier. Each margin was among the company's best June results, ranking 2 of 7 for gross margin, 2 of 6 for operating margin and 2 of 7 for net margin on comparable group-basis filings.
Revenue grew year-on-year and operating profit doubled, while net profit more than doubled. The stronger bottom line followed the operating improvement, although finance costs, tax and other below-operating items still reduced operating profit before the final earnings result. Annual equity increased year-on-year, while the share count also rose between the comparable quarters, so per-share changes should not be read as a pure operating trend.
Risks
The most important risk is cash conversion: FY2026 operating cash flow converted only 0.45 times operating profit, despite higher earnings. That raises the risk that working capital or other timing effects absorb the reported improvement.
The balance sheet itself is lightly geared at 3.8% of owners' equity, with interest cover of 8.05 times and a current ratio of 13.28 times. Total debt was LKR 190.7 million, limiting immediate financing pressure, but manufacturing conditions remain exposed to labour shortages and higher fuel and input costs. Easing rates are a supportive backdrop, while volatile energy prices remain a counterweight.
Outlook
As at 2026-08-08, the next company-specific event is the filing for the quarter ending 2026-09-30. Based on exchange filing patterns, it is expected between 2026-10-28 and 2027-01-26; that filing will show whether the latest margin improvement is sustained and whether operating cash flow catches up with profit.
The available data cannot establish the cause of the sharp margin expansion or determine whether it will persist. The sector backdrop is mixed: export competitiveness and lower rates are constructive, but labour shortages and factory input-cost pressure could challenge chemical demand and margins.